Institut Pasteur, Paris, France (NRC-Rabies IPP) (14), were also included. Furthermore, in 136 order to assess the specificity of the two RABV detection assays, a panel of 20 primary brain 137 specimens provided by NRC-Rabies IPP from a range of important animals for rabies virus 138 transmission, and previously confirmed to be negative by FAT, was also tested. In addition, 139 15 other major representatives of rhabdoviruses other than RABV and from the archive of 140 NRC-Rabies IPD were also tested. Finally, 19 clinical specimens including skin biopsy, saliva 141 and cerebrospinal fluid (CSF) samples received at NRC-Rabies IPP and collected from human 142 patients suspected of rabies infection were evaluated with both of these molecular tools. All 143 extractions from isolates provided by NRC-Rabies IPD were performed using the QIAamp® 144 Viral RNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. 145
The RNA was suspended in a final volume of 60 µl elution buffer and kept at −80°C until 146 testing. For samples and isolates provided by NRC-Rabies IPP, extraction and storage were 147 performed as previously described (31) . 148 149
3. Real-time RT-PCR (RT-qPCR) assays 150
A similar RT-qPCR protocol was used for the detection of both N and L genes. All samples 151 were tested in duplicate and RT-qPCR was performed using the Quantitect Probe RT-PCR kit 152 (Qiagen, Hilden, Germany) in a 20 µl reaction mixture containing 2x QuantiTect probe PCR master mix, 0.25 µl of QuantiTect RT mix, 400 nM PCR primers and 200 nM TaqMan 154 probes and 5 µl of 1:10 diluted RNA in RNase-free water. Positive controls containing master 155 mix with standard RNA of each system and negative controls consisting of master mix with 156 sterile RNase-free water were included in each run. The reaction was carried out on a 7500 157 Fast Real Time system cycler or on a 7500 Real Time system cycler (Applied Biosystems, Foster City, US) using the following temperature profile: 1 cycle of reverse transcription at 159 50°C for 10 min, 1 cycle of denaturation at 95°C for 15 min, followed by 40 cycles of 95°C 160 for 15 s and 60°C for 1 min. The RT-qPCR reactions were analyzed using the 7500 software 161 Serial 10-fold dilutions of standard RNAs, from 10 8 to 1 molecule, were prepared in RNase-178 free water. Corresponding mean Cq (quantification cycle) values obtained per triplicates per 179 standard dilution were then plotted proportionally to the logarithm of the input copy numbers 180 to generate a quantitative standard. 181 182
5. Analytical testing 183
The quantitative standards were used to evaluate the diagnostic assays performances such as 184 limit of detection (LOD), the coefficient of correlation (R 2 ) and the amplification efficiency 185 (E) values. The LOD value represents the concentration where at least 50% of replicates of 186 each dilution were detected. A linear model regression test was performed using R (version 187 3.0.2, The R Foundation for Statistical Computing) to determine the value of R 2 , indicating 188 the goodness of regression. The E value was calculated with the formula E = 10 (-1/slope) -1. 189 Relative RABV genome copies in tested samples was calculated through the formula q= 190 10 (Cq-b)/a ; where a is the slope, b is the intercept from a standard curve of each specific 191 target gene and Cq is the quantification cycle number. Furthermore, the Pearson correlation 192 efficient where a coefficient of 1 represents a good correlation was also calculated. 193 194 
5. 3. Determination of sensitivity 195
The sensitivity is defined as the probability that an assay give positive results in the presence 196 of specific target. This was calculated by the formula Se = d/ (d+b); where b represents the 197 number of false negatives and d is the number of true positives. Positive and negative 198 predictive values were also calculated by formulas PPV= d / (d+c) and NPV= a/ (b+a), 199
where a is the number of true negatives samples and c is the number of false positives. 200
Moreover, a ROC («Receiver Operating Characteristic») analysis was performed, using the 201 statistical software XLSAT (Version 2015 .5.01.23654, Copyright Addinsoft 1995 -2015 to 202 identify the threshold value below which the test should be considered positive. Accuracy of 203 assays was measured by the area under the ROC curve (AUC) with 95% confidential interval 204 (CI) of AUC. An area higher than 0.9 represents an excellent test and a value of 0.5, a 205 worthless test (33, 34). 206 Finally, the comparability between Cq values given by these two quantitative assays was 207 assessed using a Bland-Altman analysis where the agreement between these two 208 measurements was quantified by using a graphical approach. Statistical limits of agreement 209 are calculated by using the mean and the standard deviation of the differences between assays 210 with 95% CI (35). 211
Figures A.1 and A.2).
The TaqMan probes were labeled 5' FAM (6-carboxyfluorescein) / 3' 251 BlackBerry Quencher (BBQ) and details are listed in Table 1 . 252 253
2. Specificity 254
In order to ensure the specificity of the new systems and to evaluate the occurrence of non-255 specific cross-reactivity, 16 isolates previously characterized RABV field samples and 15 256 different rhabdoviruses other than RABV species were tested in duplicate with both of the 257 assays ( Table 2) . Fluorescent detection was obtained only with RABV isolates whereas non-258 targeted viruses were not detected. These results suggested that the designed primer pairs and 259 probes exhibited no cross-reactivity with other species of lyssavirus (with Mokola and Lagos 260 bat lyssaviruses) or other rhabdoviruses ( Table 2) . The amplicons size for some RABV 261 isolates detected with each system was verified by 2% agarose gel electrophoresis and the 262 amplified fragments were sequenced using the respective forward and reverse primers of the 263 corresponding systems. A BLAST analysis of obtained sequences showed high identity rate 264 with the target region of the RABV isolate CAR_11/001h (GenBank Ac. No. KF977826) 265 belonging to the Africa 2 phylogenetic clade. Then, these primers and probes were highly 266 selective for RABV detection. In addition, we analyzed a panel of 20 FAT-negative primary 267 brain samples from different vertebrate hosts important in RABV transmission. All were 268 negative with both assays and confirmed that specificity was complete ( Supplementary Table  269 A.2). 270 271
Analytical sensitivity 272
Diagnostic test performances of the new assays were assessed using several parameters. 273
Analytical curves generated showed a LOD of 100 and 10 copies per reaction obtained for N-274 gene assay and L-gene assay, respectively with RABV isolate SA217695SEN (Figure 1) . 275
Regression line slope values were determined for N gene and L gene assays, with -3.08 and -276 3.1, respectively, which are close to the optimal slope value of -3.3. Significant respective 277 linear regression p-values of 1.833e-09 and 6.977e-12 for N gene and L gene assays, 278 respectively, and coefficients of correlation (R 2 ) values higher than 0.99 indicated the 279 goodness of the regression lines. Furthermore, high efficiency values (E) were obtained with 280 both of these assays. A Pearson correlation test between the two regression curves revealed a 281 coefficient of 0.99 (p < 0.0001) suggesting that correlation between the Cq values obtained by 282 both RT-qPCR methods was excellent (Figure 1) . 283
To ascertain the broad detection capacity of established assays, various RABV isolates from 284 different parts of the world, were tested. Considering detection of African RABV isolates, the 285 L-gene system was able to detect all isolates tested while the N-gene assay detected only 90% 286 of strains giving no-fluorescence signal with four isolates belonging to Africa-1 lineage, 287 including isolates from Somalia (93002SOM and 93006SOM), Tanzania (96013TAN) and 288 Morocco (87012MAR) ( Table 3a) . Furthermore, the L-gene system also detected 100% of tested isolates from other counties of the world. Considering these isolates, the N-gene assay 290 had a limited detection scale (55%) with no fluorescence signal with 9 isolates from Poland 291 (96140POL), Germany (92001GER), Saudi Arabia (87001ARS), Turkey (94009TUR), Laos 292 (99008LAO), Afghanistan (02052AFG), Russia (91041RUS) and one skunk isolate from 293 USA (91004USA) ( Table 3b ) (38) . 294
Results of all previous tests summarized in Table 4 were used for sensitivity determination 295 and ROC analysis as previously described (39). A sensitivity of 100% and 78.70% (CI 95%; 296 68.40-89.00%) was found for the RABV L-gene assay and RABV N-gene assay, respectively, 297 when compared to the reference technique. In addition, a PPV of 100% for each assay and 298
NPVs of 100% and 72.91% (CI 95%; 56.76-82.79%) for L gene assay and N gene assays 299 were obtained respectively (Fischer's exact test p < 0.0001). All previously FAT-negative 300 samples provided an undetermined mean Cq value after 40 cycles. Based on the results of the 301 ROC analysis, we determined a Cq of 39.70 as the cut-off value below which reactions are 302 positives for the L-gene assay and the N-gene assay, considering a 95% confidence interval. 303 A Cq value above these cut-off values or an undetectable Cq was considered negative. An 304 AUC of 1 was determined for each assay revealing that the tests have an excellent accuracy 305 (Figure 2) . Furthermore, Bland-Altman plot analysis also reported a non-significant bias 306 (mean difference) of 1.920±6.875 (95% limits of agreement: -11.56 to 15.40), demonstrating 307 that these two methods are approximatively equivalent (Figure 3) . 308
Intra-run and inter-run CVs of 1.67 % and 2.20 %, respectively, were found for the RABV N-309 gene assay while the RABV L-gene assay showed intra-run and inter-run CVs of 1.08 % and 310 2.16 %, respectively; indicating that assays are robust and highly repeatable( Table 4) . In 311 addition, the k of 1±0.31 (95% CI; 0.38-1.61) indicates that assays are accurate, detecting 312 only RABV strains and giving 100% concordance to previous results obtained by the NRC-R 313 IPP using a RT-qPCR (31) with the same samples (p= 0.001), and concordant with the results 314 expected for this inter-laboratory trial with RABV isolates ( Table 5) . 315
Simultaneously, both RT-qPCR assays and conventional hemi-nested RT-PCR were 316 performed as previously described (22) on 13 ten-fold dilutions of the RABV isolate 317 SA217695SEN with a titer of 6.7 10 7 ID 50 /mL. The RABV L-gene assay detected until 318 0.00067 ID 50 /mL, corresponding to 28 genome copies using the L-gene quantification 319 equation. However, conventional hemi-nested RT-PCR and RABV N-gene assay presented a 320 detection limit of 6.7 ID 50 /mL, corresponding to 75 copies of genome using N-gene 321 quantification equation (Table 6) . 322
The RABV L-gene RT-qPCR assay was selected as the most sensitive technique for detection 323 of RABV and was thus applied for the screening of human clinical samples from patients 324 suspected of rabies infection. The clinical detection of RABV RNA was analyzed in duplicate 325 using a panel of human samples from the archive of the NRC-R IPP and which were 326 previously tested using a RT-qPCR assay (31). Compared to the latter technique considered as 327 the reference test, all 4 previous RABV-positive samples were correctly detected with RABV-328 L TaqMan probe assay, whereas any cross-reactivity was detected with all 15 RABV-negative 329 specimens. Thus, the proposed RABV-L gene assay gave a 100% concordance to the previous 330 diagnosis results obtained with the RT-qPCR assay performed by NRC-R IPP (31), 331 demonstrating its effectiveness to detected RABV in clinical specimens with high sensitivity, 332 and its suited use as diagnostic tool in human RABV cases ( Table 7) . 333 334 335
Discussion 336
Despite rapid and sensitive RABV methods developed in recent years (27, 28, 30, 31, 42) , 337 only a few of them have been validated for the detection of African RABV strains with a large 338 diversity of origin (21, 30, 31) . Development of rapid and suitable molecular diagnostic tools 339 for large-scale detection RABV isolates is important for routine diagnostic testing and 340 epidemiological surveillance, particularly in Africa where rabies remains endemic. In this 341 study, we developed two TaqMan real-time assays for broad detection of African RABV 342 isolates in samples and for intra-vitam diagnosis in humans and post-mortem diagnosis in 343 animals. These assays are based on conserved regions on N and L RABV genes. 344
Oligonucleotide sequences for each assay were designed for wide detectability of African 345 RABV isolates ( (22) . Regarding the specificity 346 assessment and their selectivity to detect RABV on a large range of samples, the new primers 347 pairs and probes showed a high specific rate and no cross detection of other tested 348 rhabdoviruses and none of the 6 other lyssaviruses species tested. These results were also 349 confirmed by sequencing a selected number of amplicons obtained from positive results. 350
Moreover, evaluation of the analytical sensitivity proved that assays can detect a low amount 351 of RABV RNA with estimated LODs ranging from 100 to 10 copies of RNA target per 352 reaction, which indicates that our assays are highly sensitives, similar to previously reported 353 assays for viral RNA detected by TaqMan real-time 31, 40, 41, 42) . In addition, 354 the high coefficients of determination (R 2 ) and very good efficiencies (E >100%) demonstrate that they can both be successfully applied to quantitative analysis of viral loads in tested 356 samples infected with RABV. 357 However, with the high genetic diversity of RABV, development of a single sensitive real 358 time assay covering all widely known phylogroups remains a challenge (43, 27) . During the 359 validation of the N-gene and L-gene based RT-qPCR assays, the broad detection spectrum 360 was assessed through a large panel of RABV isolates representing different continents, with a 361 focus on African isolates. Indeed, African strains were detected by both assays with a high 362 coverage rate, mainly with the L gene-based assay. Thus our assays offer good performances 363 on detection of African isolates and could be a useful complement for a recent published 364 method (31) which presents some limits in detection of RABV isolates from Senegal 365 belonging to the Africa 2 clade. Evaluation of the broad detection performance of our assays 366 on isolates from other regions of the world displayed an excellent coverage level of the 367 RABV L-gene RT-qPCR, whereas the RABV N-gene assay was limited with important non-368
African RABV strains. The reduced sensitivity of the N-gene assay despite good in silico 369 profiles and performance demonstrated by the assays could be explained with the presence of 370 secondary structure formation of the target area which may make it less accessible for the N-371 gene oligonucleotides during the 45) . All the RABV isolates tested (61 isolates 372 belonging to the phylogenetic lineage cosmopolitan and clades Africa 2 and 3) were 373 successfully detected, mainly with the L gene-based assay which provides a test with a large 374 spectrum of RABV detection. 375
Although in the comparative analysis, the L gene-based assay offered better performances 376 than the N-gene assay regarding sensitivity and predictive values, it seems reasonable to 377 perform a double-check strategy on tested samples, using both assays in order to increase 378 reliability during use in routine rabies identification or epidemiological surveys as previously 379 reported for others lyssaviruses (46, 31). Moreover, high AUC value found in ROC analysis 380 predicted that both assays are useful for accurate detection of RABV in positive samples. 381 Furthermore, the assays showed a good agreement between measurements as shown by the 382 Bland-Altman analysis results, confirming their ability to be used efficiently for RABV 383 detection. Additionally, inter-assay and intra-assay variability below 3% and strong inter-384 laboratory concordance results ensure the repeatability and the RABV specificity of the two 385 assay systems. Our assays, particularly the L-gene based assay, could be used accurately in 386 different geographical contexts for RABV detection. 387
We used ten-fold dilutions of the RABV isolate SA217695SEN with a titer of 6.7 10 7 388 ID 50 /mL and obtained with L-gene assay lower LOD value than with the hemi-nested , although it has to be confirmed with a larger panel of isolates. The L-gene based 390 assay was able to detect RABV with as low as 6.7 10 -4 ID 50 /mL and could be successfully 391 applied in RABV diagnostic process, particularly on decomposed material or samples with 392 low viral load (15, 47) . Furthermore, compared to the hemi-nested RT-PCR, the established 393 RT-qPCRs offer some important advantages in reduction of workload and run time, while 394 providing a higher sensitivity compared to the conventional RT-PCR. 395
Based on its better performances, the L gene-based assay was chosen for determination of the 396 detection capacity with clinical specimens in comparison with a previously existing RT-qPCR 397 (31) considered as the reference technique. We evaluated the usefulness of the L-gene based 398 assay for the intra-vitam diagnosis of rabies in human using a collection of positive and 399 negative specimens including skin biopsy, saliva and cerebro-spinal fluid. Compared to the 400 RT-qPCR assay from the NRC-R IPP (31) considered as the reference test, our L-gene based 401 assay provided a strong concordance and the sensitivity was also high. This technique could 402 be useful in clinical diagnostic as reliable quantitative tools for ante-mortem rabies diagnosis 403 in humans (22, 31) . 404
Finally our assays, particularly the L-gene based assay, could be a complement for existing 405 methods for rabies diagnosis (21, 31, 46, 48, 49) with a high specificity, sensitivity and 406 repeatability and more suitable for broad detection of African RABV strains. 407 408
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. . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . G . . . . . . . . . . . T .  . . . . . . . . . . . . . . . . . . . . . .   04033MAD   . . . . . . . . G . . . . . A . . . . . . .  . . . . T . . A . . T . . . . . . . . . . . . . . . . . . . . . .  . . . T . . T . . A . . T . . . . . . . . A   98002MAD   . . . . . . . . G . . . . . A . . . . . . .  . . . . T . . A . . T . . . . . . . . . . . . . . . . . . . . . .  . . . T . . T . . A . . T . . . . . . . . A   86046MAD   . . . . . . . . G . . . . . A . . . . . . .  . . . . T . . A . . T . . . . . . . . G . . . . . . . . . . . . .  . . . T . . T . . A . . T . . . . . . . . A   92029CAR   . . . . . T . . G . . . . . . . . . . . T .  . . . . T . . C . . T . . . . . . . . G . . . . . . . . . . . . .  . . . T . . . . . A . . T . . . . . . . . .   96013TAN   . . . . . T . . G . . C . . . . . . . . T .  . . . . T . . C . . T . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . T . . . . . . . . .   14015ITA   . . . . . T . . G . . C . . . . . . . . T .  . . . . T . . C . . T . . . . . . . . . . . . . . . . . A . . . .  . . . . . . . . . . . . T . . . . . . . . .   94289RWA   . . . . . T . . G . . C . . . . . . . . T .  . . . . T . . C . . T . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . T . . . . . . . . .   RV2772   . . . . . T . . G . . C . . . . . . . . T .  . . . . T . . C . . T . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . T . . . . . . . . .   87021AFS   . . . . . T . . G . . C . . A . . . . . T .  . . . . T . . C . . T . . . . . . . . . . . . . . . . . . . . . .  . . . T . . . . . . . . T . . . . . . . . .   86031MOZ   . . . . . T . . G . . C . . A . . . . . T .  . . . . T . . C . . T . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . T . . . . . . . . .   92030NAM   . . . . . T . . G . . C . . A . . . . . T .  . . . . T . . C . . T . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . T . . . . . . . . .   178J09   . . . . . T . . T . . C . . A . . . . . T .  . . . . T . . C . . T . . . . . A . . . . . . . . . . . . . . . .  . . . . . . T . . . . . T . . . . . . . . .   239K09   . . . . . T . . T . . C . . A . . . . . T .  . . . . T . . C . . T . . . . . A . . . . . . . . . . . . . . . .  . . . . . . . . . . . . T . . . . . . . . .   95049GAB   . . . . . T . . G . . . . . . . . . . . . .  . . . . T . . C . . T . . . . . . . . G . . . . . . . . . . . . .  . . . . . . . . . A . . T . . . . . . . . A   86003BRE   . . . . . T . . G . . . . . A . . . . . . .  . . . . T . . C . . T . . . . . . . . G . . . . . . . . A . . . .  . . . . . . . . . A . . T . . . . . . . . A   RV2627   . . . . . T . . G . . . . . . . . . . . . .  . . . . T . . C . . T . . . . . . . . . . . . . . A . . A . . . .  . . . . . . . . . A . . T . . . . . . . . A   04031MAR   . . . . . T . . G . . . . . . . . . . . . .  . . . . T . . C . . T . . . . . . . . . . . . . . A . . A . . . .  . . . . . . . . . A . . T . . . . . . . . A   90016MAR   . . . . . T . . G . . . . . . . . . . . . .  . . . . T . . C . . T . . . . . . . . . . . . . . A . . A . . . .  . . . . . . . . . A . . T . . . . . . . . A   08342MAR   . . . . . T . . G . . . . . T . . . . . . .  . . . . T . . C . . T . . . . . A . . . . . . . . A . . A . . . .  . . . . . . T . . A . . T . . . . . . . . A   89017MAR   . . . . . T . . G . . . . . . . . . . . . .  . . . . T . . C . . T . . . . . A . . . . . . . . A . . A . . . .  . . . . . . . . . A . . T . . . . . . . . A   93006SOM   . . . . . . . . G . . . . . . . . . . . . .  . . . . T . . C . . T . . . . . . . . G . . . . . A . . A . . . .  . . . . . . . . . A . . T . . T . . G . . A   88008ETH   . . . . . T . . G . . . . . . . . . . . . .  . . . . T . . C . . T . . . . . . . . G . . . . . A . . A . . . .  . . . . . . . . . A . . T . . . . . G . . A   RV2985   . . . . . T . . G . . . . . . . . . . . . .  . . . . T . . C . . T . . . . . . . . G . . C . . A . . A . . . .  . . . . . . . . . A . . T . . . . . G . . A   90024GUI   . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . A . . G . . . . . A . . . . . . .  . . . . T . . . . . . . . . . A . . . . . .   90021TCH   . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . T . . . . . . . . . . . . . . . . . .   96009TCH   . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . .   88003CAM   . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T .  . . . . . . . . . . . . . . . . . . . . . .   95002CAM   . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . G . . . . . . . . . . . T .  . . . . . . . . . . . . . . . . . . . . . .   86097BEN   . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . .   95047HAV   . . . . . . . . . . . . . . . . . . . . . .  . A . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . .   90012NIG   . . . . . . . . . . . . . . . . . . . . . .  . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . .   90010NIG   . . . . . . . . . . . . . . . . . . . . . .  . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . .   01007CI   . . . . . . . . . . . . . . . . . . . . . .  . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . A . . . . . . . . . . . . . . . . . 
93011MAU
. . C . . . . . . . . . . . . . . . . . . .  . A . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . .  . . . . A . . . . . . . . . . T . . G . . .
93012MAU
. . C . . . . . . . . . . . . . . . . . . .  . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . A . . . . . . . . . . . . . . . Determination of clades and subclades was done according to Troupin C, et al., 2016 (38) NRC-Rabies IPP: National Reference Renter for rabies virus database at Institut Pasteur, Paris, France 
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